Medical Device

- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for Vanta™, a high performance recharge-free implantable neurostimulator (INS) with a device life that can be optimized up to 11 years. At comparable settings, the Vanta neurostimulator offers nearly twice the device life than competitive primary cell devices. 1,2 It also utilizes Medtronic's proprietary AdaptiveStim™ technology for personalized pain relief that adapts to the patient's movement or body position using a built-in accelerometer. AdaptiveStim technology goes beyond in-office programming by automatically adjusting stimulation to maintain each patient's optimal dose. The Vanta neurostimulator also provides unmatched full-body MRI access with Medtronic SureScan™ technology. 3 Approximately 82% of SCS-implanted patients will need at least one MRI within five years of implant. 4

"Not every patient with chronic, intractable pain is an ideal candidate for a rechargeable device, so the Vanta INS represents a welcome addition to my portfolio of available treatment options," said Krishnan Chakravarthy , M.D., Ph.D., a San Diego -based interventional pain management physician. "The extended battery life, broad MRI compatibility and personalized relief through AdaptiveStim technology allow for a more hassle-free experience and greater freedom for my patients as we manage their chronic pain."

Medtronic is continually innovating to advance spinal cord stimulation therapy technologies that improve quality of life for people with chronic pain. The Vanta neurostimulator represents a 10% increase in longevity compared to PrimeAdvanced™, Medtronic's previous generation recharge-free device. It is also 20% smaller than the PrimeAdvanced neurostimulator, with a more rounded, ergonomic contouring to offer enhanced comfort. The Vanta system provides access to Snapshot™ reporting, Medtronic's proprietary data insights solution, offering clinicians objective reporting of patient activity levels to empower objective health conversations. Clinicians and their patients wishing to trial the Vanta neurostimulator may also take advantage of CareGuidePro™, a mobile application and web portal that serves as a virtual guide for patients throughout their Medtronic spinal cord stimulation therapy journey. CareGuidePro is currently in limited commercial release with a full launch expected later this summer.

"We are committed to delivering innovative solutions that meets the needs of every patient," said Charlie Covert , vice president and general manager, Pain Therapies within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. "For those who prefer or require a recharge-free device, I believe the Vanta neurostimulator offers the best hardware and features available today. We are pleased to offer this solution, which is now part of the strongest and broadest overall portfolio in this market."

Medtronic continues to focus on expanding access to its highly effective DTM™ SCS therapy through pre-clinical and clinical work. DTM SCS is currently available on the rechargeable Intellis™ SCS platform, and the company expects to share more information about its availability across the entire Medtronic spinal cord stimulator portfolio later this summer.

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

References

  1. Settings used from Abbott's Proclaim™ clinician manual. Nominal settings 12 hours per day: 50-Hz frequency, 225-μs pulse width, and 5-mA amplitude at 500-ohms impedance. Compared to flagship model 3660.
  2. Settings from Boston Scientific's Alpha™ IFU. Programmed at 4.1mA, 280us, 40 Hz, 1 area, 730 Ohms, 2 contacts.
  3. Under specific conditions. Refer to product labeling for full list of conditions.
  4. Desai MJ, Hargens LM, Breitenfeldt MD, et al. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine. 2015;40(9):E531-537.

Contacts:

Jeff Trauring

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-505-0159

+1-763-505-4626

Vanta PC Front View

Medtronic plc (PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/medtronic-announces-fda-approval-of-its-next-generation-recharge-free-spinal-cord-stimulation-platform-301309781.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 20 th Annual Global Healthcare Conference on Wednesday, September 14 th , at the Sheraton New York Hotel in New York. Joaquin Duato, Chief Executive Officer, and Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS

  • Revenues of $1.967 billion
  • Company to appeal anticipated court decision and vigorously defend XIFAXAN intellectual property
  • Balance sheet continues to improve with early retirement of $481 million of long-term debt through open market repurchases
  • Committed to strategic alternatives and will continue to evaluate the distribution of Bausch + Lomb shares as the Company works through patent litigation
  • Updates guidance

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second-quarter 2022 financial results.

"The second quarter was a transitional quarter for Bausch Health as we intensified our focus on the Bausch Pharma and Solta businesses," Thomas J. Appio , Chief Executive Officer, Bausch Health , said. "In our first ninety days, our leadership team has taken immediate action to strengthen execution and accelerate change. We have advanced debt paydown through open market repurchases this quarter. We are focused on creating value through driving growth, profitability and improving our balance sheet."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) ("the Company") announced today that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is identified.

Dr. Mammen joined Johnson & Johnson in 2017 as Global Head of Janssen R&D, and the Company thanks Dr. Mammen for his contributions in advancing Johnson & Johnson's industry-leading portfolio. The Company will continue to prioritize innovation and building new capabilities to improve the lives of the patients and consumers we serve worldwide.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Avricore Health

Healthtab™ Expands With Shoppers Drug Mart®

AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is pleased to announce that the Company is significantly expanding the number of Shoppers Drug Mart pharmacies offering its HealthTab point-of-care testing platform under a renewed Master Service Agreement (MSA) to up to 450 locations nation-wide.

In addition to Shoppers Drug Mart pharmacies, this new MSA and corresponding Statement of Work (SOW) provides for affiliated locations under the Loblaw family of brands, to utilize HealthTab upon request.

Keep reading...Show less

Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals

  • Two industry leaders join forces to empower people living with diabetes by providing information and insights to improve weight loss, glucose control and overall health
  • Collaboration will create a seamless, integrated experience between Abbott's world-leading continuous glucose monitoring device 1 and WeightWatchers' number one doctor-recommended weight loss program 2 to help individuals better understand and manage their diabetes and weight

Abbott (NYSE: ABT) and WW International, Inc. ("WeightWatchers" or "WW") today announced a strategic partnership that will help people living with diabetes better understand and manage their diabetes and weight. The companies are working together to integrate WeightWatchers' diabetes-tailored weight management program with Abbott's portfolio of FreeStyle Libre ® products to create a seamless mobile experience that will give people living with diabetes the information and insights needed to make healthy adjustments to their diet, improve their glucose levels, and, ultimately, gain more control of their health.

Maintaining a healthy body weight and having proper nutrition are critical to living well with diabetes. 3 Yet, for many people living with diabetes, determining what to eat and following a meal plan is the most challenging part of diabetes management. 4 Through this partnership, participants can receive glucose insights from Abbott's FreeStyle Libre sensor-based technology that show the impact of food choices, alongside the empirically validated 5 WeightWatchers' diabetes-tailored nutritional guidance to help them achieve their healthier living goals.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Second Quarter 2022 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2022 financial results on Thursday, August 11, 2022 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, August 11, 2022

Time : 8:30 a.m. ET

Telephone : Toll Free: 1-855-669-9657 or International 1-412-317-0790

Webcast : www.gud- knight .com or Webcast
This is a listen-only audio webcast. Media Player is required to listen to the broadcast.

Replay : An archived replay will be available for 30 days at www.gud-knight.com .


________________________________________
About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×